We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Routine Blood Test Predicts Increased Mortality Risk in COVID-19 Patients

By LabMedica International staff writers
Posted on 24 Sep 2020
Illustration
Illustration
A standard test that assesses blood cells can identify which patients who are admitted to the hospital with COVID-19 face a high risk of becoming critically ill and dying.

Early reports from China had indicated that the body's inflammatory response was extremely intense in some patients and very mild in others. Previous research had also revealed that certain changes in the numbers and types of blood cells during inflammation are associated with poor health outcomes in patients with diseases such as heart disease, cancer, and diabetes. A team of investigators at the Center for Systems Biology at Massachusetts General Hospital (Boston, MA, USA) conducted a study in which they examined 1,641 adults diagnosed with SARS-CoV-2 infection for complicated changes in circulating blood cells. The scientists first searched for patterns using currently available blood tests that are routinely performed.

"We were surprised to find that one standard test that quantifies the variation in size of red blood cells - called red cell distribution width, or RDW - was highly correlated with patient mortality, and the correlation persisted when controlling for other identified risk factors like patient age, some other lab tests, and some pre-existing illnesses," said co-author Jonathan Carlson, MD, PhD.

Patients who had RDW values above the normal range when they were admitted to the hospital had a 2.7-times higher risk of dying, with a mortality rate of 31% compared with 11% in patients with normal RDW values. Also, a subsequent increase in RDW after admission was associated with an even higher risk of dying, indicating that RDW could be tracked during hospitalization to help determine whether patients are responding to treatment or getting worse. The investigators are currently seeking to uncover the mechanisms that cause RDW elevations in severe COVID-19 cases.

"Such discoveries could point to new treatment strategies or identify better markers of disease severity," noted co-author Aaron Aguirre, MD, PhD, an MGH Cardiologist and Critical Care Physician.

Related Links:
Center for Systems Biology

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more